Antiangiogenic therapy at the ocular surface. When, what and why?;Antiangiogene Therapie am vorderen Augenabschnitt. Wann? Was? Wofür?

Ophthalmologe

Volumn 108, Issue 3, 2011, Pages 230-236

  Bock, F ^a   Regenfuss B ^a   Cursiefen, C ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Angiogenesis; Avastin; Corneal transplantation; Glaucoma surgery; Lymphangiogenesis

Indexed keywords

ANGIOGENESIS INHIBITOR;

ARTICLE; CLOSED ANGLE GLAUCOMA; CONJUNCTIVA; CONJUNCTIVA TUMOR; CORNEA NEOVASCULARIZATION; CORNEA TRANSPLANTATION; DRUG EFFECT; GRAFT SURVIVAL; HUMAN; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; MELANOMA; POSTOPERATIVE COMPLICATION; PTERYGIUM; VASCULARIZATION; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; CONJUNCTIVA; CONJUNCTIVAL NEOPLASMS; CORNEAL NEOVASCULARIZATION; CORNEAL TRANSPLANTATION; GLAUCOMA, ANGLE-CLOSURE; GRAFT SURVIVAL; HUMANS; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; MELANOMA; POSTOPERATIVE COMPLICATIONS; PTERYGIUM; VISUAL ACUITY;

EID: 79952986915     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00347-010-2262-0     Document Type: Article

References (26)

1. Bachmann B, Bock F, Wiegand S et al (2008) Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation. Arch Ophthalmol 126: 71-77.
2. Bachmann BO, Luetjen-Drecoll E, Bock F et al (2009) Transient postoperative vascular endothelial growth factor (VEGF)-neutralisation improves graft survival in corneas with partly regressed inflammatory neovascularisation. Br J Ophthalmol 93: 1075-1080.
3. Bachmann B, Taylor RS, Cursiefen C (2010) Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis. Ophthalmology 117: 1300-1305.
4. Bock F, Onderka J, Dietrich T et al (2007) Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 48: 2545-2552.
5. Bock F, König Y, Kruse FE et al (2008) Bevacizumab (Avastin®) eye drops inhibit corneal neovascularisation. Graefes Arch Clin Exp Ophthalmol 246: 281-284.
6. Chen L, Hamrah P, Cursiefen C et al (2004) Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3) mediates dendritic cell migration to lymph nodes and induction of immunity to corneal transplants. Nat Med 10: 813-815.
7. Cursiefen C, Schlötzer-Schrehardt U, Küchle M et al (2002) Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and Podoplanin. Invest Ophthalmol Vis Sci 43: 2127-2135.
8. Cursiefen C, Martus P, Nguyen NX et al (2002) Corneal neovascularization after nonmechanical versus mechanical corneal trephination for non-high-risk keratoplasty. Cornea 21: 648-652.
9. Cursiefen C, Rummelt C, Küchle M, Schlötzer-Schrehardt U (2003) Pericyte recruitment in human corneal angiogenesis. Br J Ophthalmol 87: 101-106.
10. Cursiefen C, Chen L, Borges L et al (2004) Via bone marrow-derived macrophages, VEGF A mediates lymph- and hemangiogenesis in inflammatory neovascularization. Eur J Clin Invest 113: 1040-1050
11. Cursiefen C, Maruyama K, Liu Y et al (2004) Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci 45: 2666-2673.
12. Cursiefen C, Chen L, Saint-Geniez M et al (2006) Nonvascular VEGFR3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci U S A 103: 11405-11410.
13. Cursiefen C, Bock F, Horn FK et al (2009) GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial. Ophthalmology 116: 1630-1637.
14. Dietrich T, Bock F, Yuen D et al (2010) Cutting edge: lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation. J Immunol 184: 535-539.
15. Heindl LM, Hofmann T, Adler W et al (2010) Intraocular tumor-associated lymphangiogenesis: a novel prognostic factor for ciliary body melanomas with extraocular extension? Ophthalmology 117: 334-342.
16. Heindl LM, Hofmann TN, Knorr HL et al (2009) Intraocular lymphangiogenesis in malignant melanomas of the ciliary body with extraocular extension. Invest Ophthalmol Vis Sci 50: 1988-1995.
17. Horsley MB, Kahook MY (2010) Anti-VEGF therapy for glaucoma. Curr Opin Ophthalmol 21: 112-117.
18. Hos D, Bock F, Dietrich T et al (2008) Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation. Invest Ophthalmol Vis Sci 49: 1836-1842.
19. Koenig Y, Bock F, Horn F et al (2009) Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 247: 1375-1382.
20. Küchle M, Cursiefen C, Nguyen NX et al (2002) Risk factors for corneal allograft rejection: intermediate results of a prospective normal-risk keratoplasty study. Graefes Arch Clin Exp Ophthalmol 240: 580-584.
21. Leippi S, Grehn F, Geerling G (2009) Antiangiogenic therapy for pterygium recurrence. Ophthalmologe 106: 413-419.
22. Nguyen NX, Seitz B, Martus P et al (2007) Long-term topical steroid treatment improves graft survival following normal-risk penetrating keratoplasty. Am J Ophthalmol 144: 318-319.
23. Peebo BB, Fagerholm P, Traneus-Röckert C, Lagali N (2010) Cellular-level characterization of lymph vessels in live, unlabeled corneas by in vivo confocal microscopy. Invest Ophthalmol Vis Sci 51: 830-835.
24. Regenfuss B, Bock F, Parthasarathy A, Cursiefen C (2008) Corneal (lymph)angiogenesis - from bedside to bench and back: a tribute to Judah Folkman. Lymphat Res Biol 6: 191-201.
25. Zimmermann P, Dietrich T, Bock F et al (2009) Tumor-associated lymphangiogenesis in conjunctival malignant melanoma. Br J Ophthalmol 93: 1529-1534.
26. Bock F, König Y, Dietrich T et al (2007) Inhibition of angiogenesis in the anterior chamber of the eye. Ophthalmologe 104: 336-344.